Related Experiment Video
Updated: Feb 28, 2026

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Fluoroquinolone Resistance Patterns in Multidrug-Resistant Escherichia coli from the Gut Microbiota of Young Children
Ludmila Suzhaeva1, Svetlana Egorova1, Dmitrii Polev2
1Laboratory of Identification of the Pathogens, St. Petersburg Pasteur Institute, 197101 St. Petersburg, Russia.
Insights
Multidrug-resistant Escherichia coli (E. coli) with fluoroquinolone resistance is increasing in healthy children, posing a public health risk. This resistance is linked to specific genetic mutations and the spread of resistant E. coli clones.
Area of Science:
- Microbiology
- Genetics
- Public Health
Background:
- High prevalence of fluoroquinolone-resistant E. coli in children is a significant public health concern.
- This resistance facilitates antimicrobial resistance spread and difficult-to-treat infections.
Purpose of the Study:
- Investigate fluoroquinolone resistance in multidrug-resistant (MDR) E. coli from healthy children in St. Petersburg, Russia.
- Focus on identifying fluoroquinolone resistance determinants in pediatric E. coli isolates.
Main Methods:
- Phenotypic antimicrobial susceptibility testing (AST) on 307 E. coli isolates from pediatric fecal samples (2012-2013 and 2021-2022).
- Whole-genome sequencing of 47 MDR E. coli isolates to analyze resistance mechanisms.
- Genotypic analysis of resistance determinants, including QRDR mutations and plasmid-borne genes.
Main Results:
- Significant increase in MDR E. coli strains from 15.7% to 32.5% between 2012-2022.
- Fourfold rise in resistance to third-generation cephalosporins and fluoroquinolones (CIP) over a decade.
- Distinct genotypic pathways for resistance identified: low-level NAL resistance (gyrA S83 mutation), low-level MFX resistance (qnr gene), and high-level CIP/LVX resistance (multiple QRDR mutations).
- Predominance of ST131 and ST38 clones in pediatric E. coli isolates.
Conclusions:
- Efficacy of moxifloxacin for empirical treatment of MDR E. coli infections may be compromised.
- Pediatric gut microbiota acts as a reservoir for resistant E. coli, with expansion of MDR clones potentially independent of direct antibiotic pressure.
Abstract:
Background/Objectives: The high prevalence of fluoroquinolone-resistant E. coli in healthy children represents a significant public-health risk, facilitating the spread of antimicrobial resistance and increasing the potential for difficult-to-treat extraintestinal infections with severe clinical outcomes. This study aimed to investigate the prevalence of fluoroquinolone resistance in multidrug-resistant E. coli isolated from presumptively healthy children in St. Petersburg, Russia, with a particular focus on fluoroquinolone resistance determinants. Methods: Phenotypic AST was performed on 307 E. coli isolates from fecal pediatric samples, comprising 230 isolates from 2012 to 2013 and 77 isolates from 2021 to 2022. A subset (n = 47) of MDR isolates underwent whole-genome sequencing. Results: The frequency of MDR E. coli strains rose significantly from 15.7% to 32.5% over the study period. The most significant increases in resistance among E. coli strains were to third-generation cephalosporins (CTX, CTZ) and fluoroquinolones (CIP), rising fourfold over a decade. Based on phenotypic resistance profiles of MDR E. coli to quinolones, the highest resistance rates were observed for MFX (80.9%) followed by NAL (74.5%), LVX (44.7%) and CIP (40.4%). Genotypic analysis revealed distinct pathways: low-level NAL resistance required only an S83 mutation in gyrA, whereas low-level MFX resistance was predominantly conferred by a plasmid-borne qnr gene. In contrast, resistance to CIP and LVX involved at least three QRDR mutations: S83L and D87N/Y in gyrA, and S80I in parC. Notably, our study showed the predominance of the ST131 and ST38 clones in E. coli isolated from pediatric samples. Conclusions: Our findings suggest that the efficacy of moxifloxacin for empirical treatment of infections caused by MDR E. coli might be severely compromised. Overall, the current study highlights that the pediatric gut microbiota serves as a reservoir for resistant E. coli with the expansion of multidrug-resistant clones independently of direct antibiotic selection pressure.
Related Concept Videos
Development of Antibiotic Resistance
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Stringent Response in E. coli
Gene Regulation in Microbial Communities: Quorum Sensing

